Clinical Trial Update: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating cobimetinib in refractory Langerhans cell histiocytosis and other histiocytic disorders, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erdheim-chester Disease
• Histiocytic Sarcoma
• Juvenile Xanthogranuloma
• Langerhans Cell Histiocytosis
• Malignant Histiocytic Disorders
• Neurodegenerative Disease
• Rosai-dorfman Disease

Drugs mentioned

• Cotellic (cobimetinib)

Snippet

Sponsor: Carl Allen | Conditions: Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma | Phase 2 | Status: RECRUITING